Calidi Biotherapeutics Azioni (AMEX: CLDI)

Ultime notizie per Calidi Biotherapeutics (AMEX:CLDI) Azioni

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) affirms FY2025 sales outlook from $1.46 billion-$1.49 billion to $1.46 billion-$1.49 billion vs $1.48 billion estimate.

News

Guidance

Bentley Systems says, "we continue to execute towards our financial outlook range for the year."

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) reported quarterly earnings of $2.34 per share which beat the analyst consensus estimate of $2.08 by 12.5 percent. This is a 3.08 percent increase over earnings of $2.27 per share from the same period last year. The company reported quarterly sales of $984.17 million which beat the analyst consensus estimate of $941.97 million by 4.48 percent. This is a 2.75 percent decrease over sales of $1.01 billion the same period last year.

Earnings

Earnings Beats

Charles River Q1 Adj. EPS $2.34 Beats $2.08 Estimate, Sales $984.17M Beat $941.97M Estimate

Trimble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) is looking for Q2 GAAP EPS of $0.26-$0.32 vs $0.37 analyst estimate. sees sales of $815.000 million-$845.000 million vs $826.50 million analyst estimate.

TRMB

Trimble Sees Q2 GAAP EPS $0.26-$0.32 vs $0.37 Est; Sees Sales $815.000M-$845.000M vs $826.50M Est

Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.01) by 400 percent. This is a 83.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $52.51 million which missed the analyst consensus estimate of $58.75 million by 10.62 percent. This is a 93.21 percent increase over sales of $27.18 million the same period last year.

Earnings Misses

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Q1 EPS $(0.05) Misses $(0.01) Estimate, Sales $52.51M Miss $58.75M Estimate

Trimble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) is looking for Q2 Adj EPS of $0.59-$0.65 vs $0.61 analyst estimate..

Trimble Sees Q2 Adj EPS $0.59-$0.65 vs $0.61 Est

BLMN

Bloomin Brands Q1 Adj. EPS $0.59 Beats $0.56 Estimate, Sales $1.05B Beat $1.03B Estimate

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.48 by 8.33 percent. This is a 8.33 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $3.89 billion which missed the analyst consensus estimate of $4.00 billion by 2.78 percent. This is a 1.89 percent increase over sales of $3.82 billion the same period last year.

TEVA

Teva Pharmaceutical Indus Q1 Adj. EPS $0.52 Beats $0.48 Estimate, Sales $3.89B Miss $4.00B Estimate

General

SHOO

Due To Macroeconomic Uncertainty Related To The Impact Of New Tariffs On Goods Imported Into The United States, Steve Madden Is Withdrawing The 2025 Financial Guidance Provided In Its Earnings Release On February 26, 2025 And Is Not Providing Guidance At This Time

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) function as a passive store of value is rapidly giving way to a more dynamic role as a yield-generating financial asset, according to Brendon Sedo, an initial <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38084347/core-chain-stc-bahrain-partner-to-boost-web3-adoption-in-gulf-region">contributor to Core Chain</a> and head of its investment arm, Core Ventures.
"Institutions won't settle for simple holding," Sedo told Benzinga in an interview. "They're built on generating yield. ETFs are just the first step." 
He emphasized that the real frontier lies in turning Bitcoin into a productive asset, one that offers income without relying on custodians or compromising decentralization.
Central to this transformation is Core's Timelock Plus mechanism, which enables BTC holders to earn roughly 4–6% yield natively, without wrapping their coins. 
"This eliminates the trust assumptions of custodians or bridges," said Sedo. "It transforms Bitcoin from a ‘hodl-only' asset into an income-generating primitive on its own terms."
This represents a broader shift in how the industry defines "Bitcoin DeFi." 
Historically, decentralized finance for Bitcoin required wrapping BTC to interact with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-compatible protocols, an approach that introduced significant counterparty risks. 
But innovations like Core's native staking infrastructure are enabling DeFi to exist on Bitcoin itself.
"Bitcoin DeFi is no longer defined by its dependence on external blockchains," Sedo said. "It's now about building directly on Bitcoin's own ecosystem, using its native security."
Also Read: <a href="https://www.benzinga.com/markets/25/05/45242623/ripple-commits-25m-to-us-teachers-and-classrooms-via-rlusd-stablecoin">Ripple Commits $25M To US Teachers And Classrooms Via RLUSD Stablecoin</a>
That momentum is now being backed by venture capital. 
Core Ventures, the ecosystem fund affiliated with Core Foundation, has deployed over $1 million into 15 Bitcoin-native projects since early 2024, according to a released issued Thursday. 
The portfolio spans a broad range of innovations: BTC-backed stablecoins, yield protocols, decentralized bridges and even miner-aligned security systems.
Projects such as Solv Protocol, Colend, BitFlux, BIMA Labs and Sats Terminal make up a fast-growing share of the Bitcoin utility market. Several of these are also backed by major players like Coinbase Ventures (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and OKX Ventures.
"We're not here to debate opcodes," Sedo added. "We're here to fund the people actually shipping."
With more than 6,000 BTC staked, $500 million in total value locked, and 100,000+ daily active users, Core has quickly become the anchor of Bitcoin's programmable ecosystem. 
Its goal, Sedo said, is to bridge the gap between HODLing and active capital deployment.
"For too long, those two worlds existed apart," he said. "Now, we're transforming Bitcoin into infrastructure, capital that can be used, not just held."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45231848/bitcoin-eyes-100000-experts-assert-but-will-the-federal-reserve-play-ball">Bitcoin Eyes $100,000, Experts Assert, But Will The Federal Reserve Play Ball?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

COIN

Bitcoin Is No Longer Just Digital Gold — Native Staking, Yield Are Redefining Its Role, Says Core DAO

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.57) by 96.49 percent. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $42.02 million which missed the analyst consensus estimate of $50.75 million by 17.20 percent. This is a 25.66 percent decrease over sales of $56.52 million the same period last year.

AMRN

Amarin Corp Q1 Adj. EPS $(0.02) Beats $(0.57) Estimate, Sales $42.02M Miss $50.75M Estimate

Caesarstone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTE#NASDAQ">CSTE</a>) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.38 percent. This is a 123.08 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $99.56 million which beat the analyst consensus estimate of $97.00 million by 2.64 percent. This is a 15.84 percent decrease over sales of $118.29 million the same period last year.

CSTE

Caesarstone Q1 Adj. EPS $(0.29) Beats $(0.32) Estimate, Sales $99.56M Beat $97.00M Estimate

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) is looking for Q3 Adj EPS of $1.48-$1.52 vs $1.54 analyst estimate. sees sales of $4.577 billion-$4.621 billion vs $4.53 billion analyst estimate.

Emerson Electric Sees Q3 Adj EPS $1.48-$1.52 vs $1.54 Est; Sees Sales $4.577B-$4.621B vs $4.53B Est

Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 66.67 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $39.60 million which missed the analyst consensus estimate of $48.22 million by 17.86 percent. This is a 12.93K percent increase over sales of $304.00 thousand the same period last year.

GERN

Geron Q1 EPS $(0.03) Beats $(0.04) Estimate, Sales $39.60M Miss $48.22M Estimate

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) is looking for Q3 GAAP EPS of $1.04-$1.08 vs $1.20 analyst estimate..

Emerson Electric Sees Q3 GAAP EPS $1.04-$1.08 vs $1.20 Est

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) lowers FY2025 GAAP EPS guidance from $4.42-$4.62 to $4.05-$4.20 vs $4.47 analyst estimate..

Emerson Electric Lowers FY2025 GAAP EPS Guidance from $4.42-$4.62 to $4.05-$4.20 vs $4.47 Est

Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.30 by 16.67 percent. This is a 12.9 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $370.54 million which beat the analyst consensus estimate of $366.81 million by 1.02 percent. This is a 9.70 percent increase over sales of $337.76 million the same period last year.

Bentley Systems Q1 Adj. EPS $0.35 Beats $0.30 Estimate, Sales $370.54M Beat $366.81M Estimate

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) raises FY2025 Adj EPS guidance from $5.85-$6.05 to $5.90-$6.05 vs $5.91 analyst estimate. Raises FY2025 sales outlook from $17.75 billion-$18.10 billion to $18.19 billion vs $17.91 billion estimate.

Emerson Electric Raises FY2025 Adj EPS Guidance from $5.85-$6.05 to $5.90-$6.05 vs $5.91 Est; Raises FY2025 Sales Guidance from $17.75B-$18.10B to $18.19B vs $17.91B Est

CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $1.96 by 9.69 percent. This is a 11.98 percent increase over earnings of $1.92 per share from the same period last year. The company reported quarterly sales of $5.20 billion which beat the analyst consensus estimate of $4.93 billion by 5.37 percent. This is a 6.69 percent increase over sales of $4.87 billion the same period last year.

CDW Q1 Adj. EPS $2.15 Beats $1.96 Estimate, Sales $5.20B Beat $4.93B Estimate

Trimble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) affirms FY2025 Adj EPS guidance from $2.76-$2.98 to $2.76-$2.98 vs $2.87 analyst estimate..

Trimble Affirms FY2025 Adj EPS Guidance of $2.76-$2.98 vs $2.87 Est

Steven Madden Q1 Adj. EPS $0.60 Beats $0.45 Estimate, Sales $551.38M Miss $557.34M Estimate

Press Releases

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Financing

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Management

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

Health Care

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy  Platform at AACR Annual Meeting

CLDI

MTEM

ABVC BioPharma

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Equillium

Ernexa Therapeutics

GlycoMimetics

Geovax Labs

HOOKIPA Pharma

IN8bio

Kairos Pharma

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Leap Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

NextCure

BiomX

Portage Biotech

Rallybio

SAB Biotherapeutics

Synlogic

Unity Biotechnology

Ladenburg Thalmann

Baird

HC Wainwright & Co.

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

CADL

CGON

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Comments

Calidi Biotherapeutics

Notizie

Ultime notizie per Calidi Biotherapeutics (AMEX:CLDI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO